CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Impact of final stent dimensions on long-term results following sirolimus-eluting stent implantation: serial intravascular ultrasound analysis from the sirius trial Intravascular ultrasound guidance improves clinical outcomes during implantation of both first- and second-generation drug-eluting stents: a meta-analysis 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines Discrepancies in Measurement of the Thoracic Aorta: JACC Review Topic of the Week Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk Prognostic implications of baseline 6‐min walk test performance in intermediate risk patients undergoing transcatheter aortic valve replacement Economic and Quality-of-Life Outcomes of Natriuretic Peptide–Guided Therapy for Heart Failure Negative Risk Markers for Cardiovascular Events in the Elderly Chimney technique in a TAVR-in-TAVR procedure with high risk of left main artery ostium occlusion Colchicine Reduces Cardiovascular Events in Chronic Coronary Disease

Original ResearchVolume 74, Issue 13 Supplement, October 2019

JOURNAL:J Am Coll Cardiol. Article Link

Impact of Intravascular Ultrasound-Guided Drug-Eluting Stent Implantation on Patients With Chronic Kidney Disease: Subgroup Analysis From ULTIMATE Trial

JJ Zhang, XF Gao, the ULTIMATE Investigators. Keywords: IVUS guidance vs angiography guidance; TVF; CKD

ABSTRACT


BACKGROUND - Patients with chronic kidney disease (CKD) present more frequently with complex and extensive lesions, and intravascular ultrasound (IVUS)–guided drug-eluting stent (DES) implantation is associated with improved clinical outcomes in complex lesions. However, it still remains controversial that routine IVUS guidance could be beneficial to CKD patients.


METHODS - This study aimed to investigate the impact of IVUS- or angiography-guided DES implantation on patients with CKD based on the database from the ULTIMATE trial.


RESULTS - Estimated glomerular filtration rate (eGFR) was available in 1,443 patients, with mean eGFR 81.41 ± 28.92 ml/min/1.73 m2, of whom 723 were in the IVUS guidance group and 720 in the angiography guidance group. Finally, CKD was present in 349 (24.2%) patients. At 12 months, the target vessel failure (TVF) in the CKD group was 7.2%, significantly higher than 3.2% in the no CKD group (hazard ratio [HR]: 2.30; 95% CI: 1.38 to 3.84; p = 0.001), mainly driven by increased risk of cardiac death (2.9% vs. 0.5%; p < 0.001) in CKD patients. Moreover, there were 25 TVFs in CKD patients, with 7 (3.9%) in the IVUS group and 18 (10.7%) in the angiography group (HR: 0.35; 95% CI: 0.15 to 0.84; p = 0.01) (Figure), while 35 TVFs occurred in patients without CKD, with 14 (2.6%) in the IVUS group and 21 (3.8%) in the angiography group (HR: 0.67; 95% CI: 0.34 to 1.32; p = 0.25; p for interaction = 0.24). The reduced risk of TVF in the IVUS group for CKD patients was mainly driven by the lower risk of TVMI (0.6% vs. 3.6%; borderline p = 0.05) and TVR (1.1% vs. 4.7; p = 0.04).


CONCLUSION - The present study demonstrated that CKD patients undergoing DES implantation had a higher risk of TVF during 12 months of follow-up. More importantly, the risk of TVF in CKD patients could be significantly decreased through IVUS guidance compared with angiography guidance.